BillionToOne Selects Northstar Select as Liquid Biopsy Platform for Japan's LC-SCRUM-TRY Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 06 2026
0mins
Source: Newsfilter
- Liquid Biopsy Selection: BillionToOne's Northstar Select has been chosen as the liquid biopsy platform for the LC-SCRUM-TRY study, aiming to analyze genomic characteristics of approximately 2,000 advanced non-small cell lung cancer patients through a non-invasive method, thereby enhancing understanding and treatment options for drug-resistant cancers.
- Technical Advantage: The single-molecule NGS platform of Northstar Select detects variant allele frequencies as low as 0.15%, significantly outperforming other liquid biopsy tests, ensuring higher sensitivity in clinical applications to meet the urgent precision medicine needs of lung cancer patients in Japan.
- Clinical Validation: In the LC-SCRUM-Asia genetic screening study, Northstar Select demonstrated its accuracy by comparing tumor tissue and plasma samples from about 1,000 patients, facilitating its broader adoption in Japan.
- Medicare Coverage: The test has met Medicare coverage criteria, ensuring that more advanced cancer patients can access personalized treatment options, further enhancing BillionToOne's market position in the molecular diagnostics field.
Analyst Views on BLLN
About BLLN
BillionToOne, Inc. is a precision diagnostics company that quantifies biology to create molecular diagnostics. The Company's proprietary molecular counting platform is designed to detect and measure deoxyribonucleic acid (DNA) molecules at a single-count level to help improve disease detection. It applies the proprietary technology to non-invasive prenatal screening (Prenatal) and liquid biopsy (Oncology). Its Quantitative Counting Templates (QCTs), power its ability to detect and measure tiny and sparse disease-related DNA fragments, or molecules, at the single base-pair level. These include pregnancy-related DNA that code for recessively inherited conditions such as sickle cell disease and cystic fibrosis and ctDNA in the case of cancer. Its prenatal products include UNITY Complete, UNITY Fetal Risk Screen, UNITY Aneuploidy Screen, UNITY Fetal RhD NIPT, UNITY Fetal Antigen NIPT, and UNITY Fetal Antigen CTA NIPT. Its oncology products include Northstar and Northstar Select.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
